Lifesci Capital Begins Coverage on Neurogene (NASDAQ:NGNE)

Lifesci Capital assumed coverage on shares of Neurogene (NASDAQ:NGNE) in a research report issued on Monday, MarketBeat.com reports. The brokerage set an “outperform” rating and a $50.00 price target on the stock. Lifesci Capital’s price objective suggests a potential upside of 151.64% from the stock’s current price.

A number of other analysts also recently commented on NGNE. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Neurogene in a research report on Tuesday, January 13th. Finally, Wall Street Zen downgraded Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Neurogene has an average rating of “Moderate Buy” and an average price target of $44.00.

Neurogene Stock Up 3.9%

Shares of Neurogene stock opened at $19.87 on Monday. The business has a fifty day simple moving average of $19.69 and a 200-day simple moving average of $22.01. Neurogene has a fifty-two week low of $6.88 and a fifty-two week high of $37.27. The firm has a market cap of $307.79 million, a price-to-earnings ratio of -4.83 and a beta of 1.60.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.27. Analysts anticipate that Neurogene will post -4.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NGNE. Balyasny Asset Management L.P. purchased a new stake in Neurogene in the 3rd quarter worth approximately $12,114,000. Jennison Associates LLC increased its stake in shares of Neurogene by 55.0% in the second quarter. Jennison Associates LLC now owns 167,563 shares of the company’s stock worth $2,505,000 after acquiring an additional 59,479 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Neurogene by 81.6% in the second quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock worth $1,426,000 after acquiring an additional 42,880 shares during the last quarter. Schroder Investment Management Group purchased a new stake in shares of Neurogene during the second quarter worth $451,000. Finally, Brevan Howard Capital Management LP acquired a new stake in Neurogene during the third quarter valued at $223,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.